Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Study Title
- Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel
Teva Identifier
- NEUGR-002
ClinicalTrials.gov Identifier
- NCT00837265
Study Status
- Completed
Trial Condition(s)
- Chemotherapy-induced Neutropenia
Interventions
- Biological: Neugranin | Drug: Pegfilgrastim | Drug: Chemotherapy
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years and older
Trial Duration
- 08/01/2008 - 07/01/2010
Phase
- Phase 2/3
Study Type
Interventional
